Funder: Horizon 2020; doi: http://dx.doi.org/10.13039/501100007601Funder: Cancer Research UKFunder: Mark Foundation For Cancer Research; doi: http://dx.doi.org/10.13039/100014599Abstract: Purpose: To develop a precision tissue sampling technique that uses computed tomography (CT)–based radiomic tumour habitats for ultrasound (US)-guided targeted biopsies that can be integrated in the clinical workflow of patients with high-grade serous ovarian cancer (HGSOC). Methods: Six patients with suspected HGSOC scheduled for US-guided biopsy before starting neoadjuvant chemotherapy were included in this prospective study from September 2019 to February 2020. The tumour segmentation was performed manually on the pre-biopsy contrast-enhanced CT scan. S...
Cancer of the ovary is the second most common gynaecological malignancy and is the 5th leading cause...
In the European countries, age standardized incidence rates (European standard) for ovarian cancer v...
Background High tumor dissemination (HTD) is a major risk factor for serious morbidity after primary...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Purpose: To develop a precision tissue sampling technique that uses computed tomography (CT)–based r...
Funder: This project has received funding from the European Union’s Horizon 2020 research and innova...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
Abstract: Background: Ovarian cancer survival rates have not changed in the last 20 years. The major...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
Objectives: To determine if radiomic features, alone or combined with clinical data, are associated ...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
International audiencePURPOSE:To evaluate the associations between clinical outcomes and radiomics-d...
PurposeTo develop and validate a radiomics model for predicting preoperative lymph node (LN) metasta...
Cancer of the ovary is the second most common gynaecological malignancy and is the 5th leading cause...
In the European countries, age standardized incidence rates (European standard) for ovarian cancer v...
Background High tumor dissemination (HTD) is a major risk factor for serious morbidity after primary...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Purpose: To develop a precision tissue sampling technique that uses computed tomography (CT)–based r...
Funder: This project has received funding from the European Union’s Horizon 2020 research and innova...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
Abstract: Background: Ovarian cancer survival rates have not changed in the last 20 years. The major...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
Objectives: To determine if radiomic features, alone or combined with clinical data, are associated ...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
International audiencePURPOSE:To evaluate the associations between clinical outcomes and radiomics-d...
PurposeTo develop and validate a radiomics model for predicting preoperative lymph node (LN) metasta...
Cancer of the ovary is the second most common gynaecological malignancy and is the 5th leading cause...
In the European countries, age standardized incidence rates (European standard) for ovarian cancer v...
Background High tumor dissemination (HTD) is a major risk factor for serious morbidity after primary...